ValiRx plc
VAL.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £50 | £10 | £0 | £0 |
| % Growth | 418.5% | – | – | – |
| Cost of Goods Sold | £0 | £256 | £224 | £229 |
| Gross Profit | -£217 | -£246 | -£224 | -£229 |
| % Margin | -436.4% | -2,562.9% | – | – |
| R&D Expenses | £245 | £383 | £551 | £304 |
| G&A Expenses | £1,976 | £1,886 | £1,502 | £1,216 |
| SG&A Expenses | £1,976 | £1,668 | £1,502 | £1,216 |
| Sales & Mktg Exp. | £0 | -£218 | £0 | £0 |
| Other Operating Expenses | -£30 | £0 | £540 | £158 |
| Operating Expenses | £2,191 | £2,052 | £2,593 | £1,678 |
| Operating Income | -£2,142 | -£2,299 | -£2,593 | -£1,678 |
| % Margin | -4,302.7% | -23,943.1% | – | – |
| Other Income/Exp. Net | £11 | -£4 | -£5 | -£3 |
| Pre-Tax Income | -£2,130 | -£2,303 | -£2,599 | -£1,681 |
| Tax Expense | -£128 | -£175 | -£193 | -£133 |
| Net Income | -£1,916 | -£2,038 | -£2,406 | -£1,547 |
| % Margin | -3,848.7% | -21,226.1% | – | – |
| EPS | -0.015 | -0.02 | -0.031 | -0.024 |
| % Growth | 27.9% | 35.4% | -30.7% | – |
| EPS Diluted | -0.015 | -0.02 | -0.031 | -0.024 |
| Weighted Avg Shares Out | 131,774 | 101,570 | 77,302 | 65,005 |
| Weighted Avg Shares Out Dil | 131,774 | 101,570 | 77,302 | 65,005 |
| Supplemental Information | – | – | – | – |
| Interest Income | £12 | £0 | £0 | £0 |
| Interest Expense | £1 | £4 | £5 | £3 |
| Depreciation & Amortization | £267 | £254 | £224 | £229 |
| EBITDA | -£1,862 | -£2,044 | -£2,369 | -£1,449 |
| % Margin | -3,741.2% | -21,295.2% | – | – |